GLP-1 Drugs Show 30 Percent Reduction in Breast Cancer Risk in Large New Study
A large study published in June 2026 found that GLP-1 weight loss drugs are associated with a 30 percent reduction in breast cancer risk. Researchers said the finding adds to growing evidence that these medications may have benefits beyond weight management.
A large study published in June 2026 found that GLP-1 receptor agonist drugs, widely used for weight loss and diabetes management, are associated with a 30 percent reduction in breast cancer risk. The finding adds to a growing body of research suggesting these medications may have significant health benefits beyond their primary use.
The study analyzed data from hundreds of thousands of patients who had been prescribed GLP-1 drugs, including semaglutide and tirzepatide, and compared their cancer rates to those of similar patients who had not taken the medications.
Researchers said the reduction in breast cancer risk was statistically significant and held up after controlling for factors including age, weight, and other health conditions. The mechanism behind the effect is not fully understood, but researchers believe it may be related to the drugs' effects on insulin levels and inflammation, both of which are linked to cancer risk.
The findings come as GLP-1 drugs have become among the most prescribed medications in the United States. Millions of Americans are currently taking these drugs for weight loss, and their use continues to grow.
Oncologists said the results are promising but cautioned that more research is needed before the drugs could be recommended specifically for cancer prevention. They said patients should not start taking GLP-1 drugs solely based on this finding.
Separate research published around the same time found that GLP-1 users may experience decreased physical activity, a side effect that researchers said warrants monitoring.
